Search for a trial

Pharmacokinetics of micafungin in critically ill patients with invasive candidiasis.

Establish the pharmacokinetic parameters of micafungin in critically ill patients and determine whether pharmacokinetic parameters and plasma concentrations of micafungin correlate with disease severity.

Anidulafungin pharmacokinetics given as a single intravenous dose to obese patients (ADOPT).

The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin administered to obese patients with a BMI >= 40 kg/m2. The secondary objective of this trial is as follows:• To simulate pharmacokinetics…

Pharmacologic optimization of voriconazole; a prospective cluster randomized controlled trial of therapeutic drug monitoring

The objective of this study proposal is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient outcomes (efficacy and safety) and is more cost-effective compared to…

Pharmacokinetics and optimal dosage of caspofungin in critically ill patients with suspected invasive candidiasis.

Determine the pharmacokinetics of caspofungin, and the optimal dosage of caspofungin in relation to adequate exposure in critically ill patients.

Bioavailability of voriconazole in critically ill patients

The objective of this study is to obtain the absolute bioavailability of voriconazole in critically ill ICU patients.

Pharmacokinetics of the addition of an acidic beverage to posaconazole co-administered with a proton pump inhibitor in GVHD patients

to investigate whether the bioavailability of posaconazole in graft-versus-host-disease (GVHD) patients, adversely affected by the coadministration of proton pump inhibitors (PPIs), can be restored by an acidic beverage

Pharmacokinetics of anidulafungin in critically ill patients with invasive candidiasis

To investigate the correlation of pharmacokinetic parameters of anidulafungin with markers for disease severity and plasma protein levels.

Micafungin (Mycamine®) pharmacokinetics given as a single intravenous dose to obese patients (MICADO).

Primary objective:To determine the effect of obesity (BMI > 40kg/m2) on the pharmacokinetics of micafungin and develop a dosing regimen for obese patients. Secondary objective:* To describe the pharmacokinetics of the approved dose of 200mg…

Pharmacokinetics of posaconazole (Noxafil(R)) as prophylaxis for invasive fungal disease

• To determine the pharmacokinetics of posaconazole (new solid oral and IV) given as prophylaxis to patients who are at risk for developing fungal infections after receiving conditioning therapy (except strictly non myeloablative (NMA)) for…

Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections

This study has been transitioned to CTIS with ID 2024-518305-17-01 check the CTIS register for the current data. Primary objective:• To establish an improved fluconazole dosing regimen for paediatric and adolescent patients aged 2-18 years.…

A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patients

To deliver proof of concept that antifungal prophylaxis with posaconazole in addition to standard of care (SOC) can reduce the incidence of IAA in ICU patients with severe influenza, in comparison with SOC alone.To assess differences in cytokine…

Liposomal amphotericin B (Ambisome) pharmacokinetics given as a single intravenous dose to obese patients (ASPEN).

The overall aim is develop a rational dosing regimen of liposomal amphotericin B in obese patients. To achieve this goal we have defined the following objectives: Primary objective:* To determine the pharmacokinetics of liposomal amphotericin B…

Fluconazole pharmacokinetics, including bioavailability, in Obese subjects after an Intravenous and oral Administration (FOLIA).

Primary objective: To determine the effect of obesity (BMI *35 kg/m2) on the pharmacokinetics, including oral bioavailability of fluconazole.Secondary objective: To develop an optimal dosing regimen for obese patients.

Pharmacokinetics of posaconazole given as a single intravenous dose to obese subjects: Dosing Obese with Noxafil® Under a Trial (DONUT).

Primary objective:To determine the effect of obesity (BMI > 35 kg/m2) on the pharmacokinetics of posaconazole and develop a dosing regimen for obese patients. Secondary objective:• To describe the pharmacokinetics of the augmented dose of 400…